Shouhui Group (HKSE:02621) Research & Development: HK$53 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02621 Shouhui Group Ltd HKSE:02621
18 GF Score
Price HK$3.13
! 4 Warning Signs
View Full Analysis

What is Shouhui Group Research & Development?

Shouhui Group HKSE:02621 -1.88% 18 Research & Development is HK$53 Mil as of Dec. 2025. GuruFocus rates HKSE:02621 with a GF Score™ of 18/100. The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Shouhui Group's Research & Development for the six months ended in Dec. 2025 was HK$28 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was HK$53 Mil.

Shouhui Group  (HKSE:02621) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Shouhui Group Research & Development Related Terms

Shouhui Group Research & Development Historical Data

* Premium members only.

The historical data trend for Shouhui Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shouhui Group Research & Development Chart

Shouhui Group Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Research & Development
59.75 66.81 54.40 53.49

Shouhui Group Semi-Annual Data
Dec22 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial 0.00 29.73 24.92 25.08 28.14
HKSE:02621
18GF Score
Shouhui Group Ltd HKSE:02621
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shouhui Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of HK$53 Mil mean?
Shouhui Group (HKSE:02621) has a Research & Development of HK$53 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Shouhui Group and its competitors.
Is Shouhui Group's Research & Development too high?
Shouhui Group's current Research & Development is HK$53 Mil. Overall, Shouhui Group has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Shouhui Group's Research & Development compare to MRSH and AON?
Shouhui Group's Research & Development of HK$53 Mil can be compared against companies in the Insurance industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for an Insurance company?
A good Research & Development depends on the Insurance industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Shouhui Group and its competitors. Shouhui Group's current Research & Development is HK$53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shouhui Group stock overvalued right now?
Shouhui Group (HKSE:02621) has a current Research & Development of HK$53 Mil. The current Research & Development is HK$53 Mil. Shouhui Group's overall GF Score™ is 18/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Shouhui Group (HKSE:02621), the current Research & Development is HK$53 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shouhui Group Business Description

Address No. 2 Gonghua Road, 2, 4, 5-402, Building No.1, Tianjin International Jewellery City, Huayuan Industrial Zone, Binhai High-Tech Zone, Tianjin, CHN
Shouhui Group Ltd is a life and health insurance intermediary service provider in China, dedicated to providing insurance service solutions to policyholders and the insured online through life and health insurance transaction and service platforms. It distribute life and health insurance products through three distribution platforms, namely (1) online direct distribution on Xiaoyusan, (2) distribution via insurance agents on Kachabao, and (3) distribution with the assistance of business partners on Niubao 100. It operates in two reportable segments: Insurance transaction services and Insurance technology services. Key revenue is generated from Insurance transaction services which acts as the agent in distributing insurance products on behalf of the insurance companies.
18GF Score

Get the complete analysis for HKSE:02621

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$3.13
Price